A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Indoximod (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 02 Nov 2017 According to a NewLink Genetics Corporation media release, the company expects to present final results from the study at an oncology meeting in the first half of 2018.
    • 28 Jul 2017 According to a NewLink Genetics Corporation media release, the company expects to present updated phase II data from the study at an oncology meeting in late 2017 or early 2018.
    • 04 May 2017 According to a NewLink Genetics Corporation media release, data from this study will be presented at an medical meeting in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top